Use of a L. Casei Strain For the Preparation of a Composition for Inhibiting Mast Cell Activation

• US 20100284973A1
• Filed: 12/01/2008
• Published: 11/11/2010
• Est. Priority Date: 11/30/2007
• Status: Abandoned Application

• Current Assignee: Compagnie Gervais Danone (Groupe Danone), Institut Pasteur
• Original Assignee: Compagnie Gervais Danone (Groupe Danone), Institut Pasteur
• Inventors: Daëron, Mare, Schiffer-Mannioui, Cécile, Samson, Sandrine, Bourdet-Sicard, Raphaëlle
• Application Number:
  US12/745,079
• Publication Number:
  US 20100284973A1
• Time in Patent Office: Days
• US Class Current: 424/93.4
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: G01N 2333/525 Tumor necrosis factor [TNF]
• CPC Class Codes: G01N 2333/924 acting on glycosyl compounds (3.2)
• CPC Class Codes: G01N 2800/24 Immunology or allergic disorders SLE G01N2800/104
• CPC Class Codes: G01N 33/5047 Cells of the immune system

Abstract

The present invention pertains to the field of prevention and treatment of chronic or acute diseases involving mast cells, such as allergy and some autoimmune diseases. More precisely, the present invention concerns the use of probiotics containing a L. casei strain and/or a B. breve strain for inhibiting mast cell activation. The present invention relates also to screening processes for identifying bacterial strains which can be used for preparing said probiotics.

Claims

1. A method for inhibiting mast cell activation comprising contacting the mast cell with a composition comprising an L. casei strain and/or a B. breve strain.

2. The method of claim 1, wherein the composition contains an amount of L. casei strain and/or a B. breve strain effective for preventing IgE-induced mast cell activation.

3. The method of claim 2, wherein the composition contains an amount of L. casei strain and/or a B. breve strain effective for preventing, alleviating or treating an allergy or allergic manifestations.

4. The method of claim 1, wherein the composition contains an amount of L. casei strain and/or a B. breve strain effective for preventing IgG-induced mast cell activation.

5. The method of claim 4, wherein the composition contains an amount of L. casei strain and/or a B. breve strain effective for preventing, alleviating or treating an autoimmune disease.

6. The method of claim 1, wherein the composition contains an amount of L. casei strain and/or a B. breve strain effective for the preparation of a composition for preventing, alleviating or treating type 2 diabetes.

7. The method of claim 1, wherein said L. casei strain is a L. casei ssp. Paracasei strain.

8. The method of claim 1, wherein said L. casei strain is the strain deposited at the CNCM on Dec. 30, 1994, under the number I-1518.

9. The method of claim 1, wherein said Bifidobacterium breve strain is the strain deposited at the CNCM under the number I-2219, on May 31, 1999.

10. The method of claim 1, wherein said composition is a food supplement and/or a functional food.

11. The method of claim 1, wherein said composition is a fermented dairy product.

12. The method of claim 1, wherein said composition further comprises at least one other bacterial strain selected from the genera Lactobacillus, Lactococcus and Streptococcus.

13. The method of claim 12, wherein said composition comprises at least one bacterial strain selected in the group consisting of Streptococcus thermophilus and Lactobacillus bulgaricus.

14. The method of claim 1, wherein said composition is a medicinal product.

15. The method of claim 1, wherein said bacteria are used alive.

16. The method of claim 1, wherein said bacteria are used as whole dead cells.

17. The method of claim 1, wherein said composition comprises a bacterial lysate or a bacterial fraction of said bacteria.

18. The method of claim 1, wherein said composition is formulated so that uptake of this composition leads to a direct contact between mast cells and the bacteria, bacterial lysate and/or bacterial fraction comprised in said composition.

19. A screening process for identifying bacterial strains which can be used for preparing compositions for inhibiting mast cell activation by antibodies, wherein said process comprises the following steps:

(a) incubating mast cells with the bacteria to be screened, during at least one hour;

(b) optionally, removing said bacteria;

(c) adding an activating agent to mast cells; and

(d) measuring the activation of mast cells.

20. The screening process of claim 19, wherein the activating agent used in step (c) is selected in the group consisting of preformed IgG/antigen complexes, calcium ionophore, LPS, PMA, ionomycin, thapsigargine and mixtures of two or more of those.

22. The screening process according to claim 19, wherein step (d) or (e) is performed by measuring the level of beta-hexosaminidase and/or TNF-alpha released by the mast cells and/or any product released or secreted by mast cells and/or any cells alteration associated with mast cell activation.

21. A screening process for identifying bacterial strains which can be used for preparing compositions for inhibiting mast cell activation by antibodies, wherein said process comprises the following steps:

(a) incubating mast cells with the bacteria to be screened, during at least one hour;

(b) optionally, removing said bacteria;

(c) incubating mast cells with IgE antibodies;

(d) adding specific antigen to mast cells; and

(e) measuring the activation of mast cells.